BR112019000166A2 - anticorpos com baixa imunogenicidade e usos dos mesmos - Google Patents

anticorpos com baixa imunogenicidade e usos dos mesmos

Info

Publication number
BR112019000166A2
BR112019000166A2 BR112019000166A BR112019000166A BR112019000166A2 BR 112019000166 A2 BR112019000166 A2 BR 112019000166A2 BR 112019000166 A BR112019000166 A BR 112019000166A BR 112019000166 A BR112019000166 A BR 112019000166A BR 112019000166 A2 BR112019000166 A2 BR 112019000166A2
Authority
BR
Brazil
Prior art keywords
antibodies
low immunogenicity
immunogenicity
methods
binding fragments
Prior art date
Application number
BR112019000166A
Other languages
English (en)
Inventor
Hadjivassiliou Haralambos
C Johnson Jeffrey
Sun Jeonghoon
Hariharan Kandasamy
Dearth Lawrence
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of BR112019000166A2 publication Critical patent/BR112019000166A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

são fornecidos neste documento anticorpos e seus fragmentos de ligação a antígeno com baixa imunogenicidade ou nenhuma imunogenicidade em seres humanos e, opcionalmente, com propriedades de fabricação desejáveis. são também fornecidas composições que compreendem esses anticorpos ou fragmentos de ligação a antígeno, métodos de uso desses anticorpos e métodos para a produção desses anticorpos.
BR112019000166A 2016-07-06 2017-07-05 anticorpos com baixa imunogenicidade e usos dos mesmos BR112019000166A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662359150P 2016-07-06 2016-07-06
PCT/US2017/040653 WO2018009499A1 (en) 2016-07-06 2017-07-05 Antibodies with low immunogenicity and uses thereof

Publications (1)

Publication Number Publication Date
BR112019000166A2 true BR112019000166A2 (pt) 2019-10-01

Family

ID=60913146

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019000166A BR112019000166A2 (pt) 2016-07-06 2017-07-05 anticorpos com baixa imunogenicidade e usos dos mesmos

Country Status (19)

Country Link
US (1) US11427632B2 (pt)
EP (1) EP3481862A4 (pt)
JP (1) JP7120989B2 (pt)
KR (1) KR20190035737A (pt)
CN (1) CN109689684B (pt)
AR (1) AR108975A1 (pt)
AU (1) AU2017292752B2 (pt)
BR (1) BR112019000166A2 (pt)
CA (1) CA3029977A1 (pt)
CL (1) CL2019000019A1 (pt)
CO (1) CO2019001112A2 (pt)
EA (1) EA201990218A1 (pt)
EC (1) ECSP19008417A (pt)
IL (1) IL264009A (pt)
MX (1) MX2019000172A (pt)
SG (1) SG11201811788SA (pt)
TW (1) TW201811824A (pt)
WO (1) WO2018009499A1 (pt)
ZA (1) ZA201900070B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11401329B2 (en) 2017-08-02 2022-08-02 Phanes Therapeutics, Inc. Anti-CD47 antibodies and uses thereof
KR102115300B1 (ko) * 2018-06-01 2020-05-26 재단법인 목암생명과학연구소 항체 라이브러리 및 이를 이용한 항체 스크리닝 방법
TW202104260A (zh) 2019-04-05 2021-02-01 美商西建公司 腫瘤選擇性結合ｃｄ４７之抗體之工程
US20200400662A1 (en) 2019-06-07 2020-12-24 ALX Oncology Inc. Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
US20230365681A1 (en) 2020-10-07 2023-11-16 Celgene Corporation Bispecific antibody treatment of lymphoid malignant neoplasm conditions
US20220196651A1 (en) 2020-12-06 2022-06-23 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1892296A1 (en) 1988-09-02 2008-02-27 Dyax Corporation Generation and selection of recombinant varied binding proteins
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
GB9026912D0 (en) 1990-12-11 1991-01-30 Wessex Instrumentation Limited Reaction detection equipment
CA2108147C (en) 1991-04-10 2009-01-06 Angray Kang Heterodimeric receptor libraries using phagemids
AU2238292A (en) 1991-06-14 1993-01-12 Xoma Corporation Microbially-produced antibody fragments and their conjugates
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
AU725609C (en) * 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
US7321026B2 (en) * 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
EP2316487B1 (en) * 2003-04-11 2014-06-11 MedImmune, LLC Recombinant IL-9 antibodies & uses thereof
US20060228350A1 (en) 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
ATE493441T1 (de) 2003-10-16 2011-01-15 Micromet Ag Multispezifische deimmunisierte cd3-bindende moleküle
US7354854B2 (en) 2005-05-24 2008-04-08 Texas Instruments Incorporated Nickel silicide method and structure
CA2609234C (en) 2005-06-01 2014-04-22 Micromet Ag Anti-il2 antibodies
WO2007126799A2 (en) 2006-03-30 2007-11-08 Novartis Ag Compositions and methods of use for antibodies of c-met
EP2716657A3 (en) 2006-12-20 2014-10-08 Mmrglobal, Inc. Antibodies and methods for making and using them
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
JP5914353B2 (ja) 2009-12-23 2016-05-11 エスバテック − ア ノバルティス カンパニー エルエルシー 免疫原性を減少させるための方法
DK2536764T3 (en) 2010-02-18 2018-09-17 Ose Immunotherapeutics ANTI-CD28 HUMANIZED ANTIBODIES
PL2812443T3 (pl) * 2012-02-06 2020-01-31 Inhibrx, Inc. Przeciwciała CD47 i sposoby ich zastosowania
JP6498600B2 (ja) 2012-06-08 2019-04-10 ストロ バイオファーマ インコーポレーテッド 部位特異的な非天然アミノ酸残基を含む抗体、その調製方法、及びその使用方法
CN104981254B (zh) 2012-08-31 2018-05-22 苏特罗生物制药公司 含有叠氮基的经修饰的氨基酸
ES2944477T3 (es) 2013-02-06 2023-06-21 Inhibrx Inc Anticuerpos CD47 no reductores de plaquetas y no reductores de glóbulos rojos y métodos de uso de los mismos
WO2016073906A2 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related immunoassays
JP6857603B2 (ja) 2014-11-18 2021-04-14 ヤンセン ファーマシューティカ エヌ．ベー． 抗ｃｄ１４７抗体、方法及び使用
SG11201705310TA (en) * 2014-12-30 2017-07-28 Celgene Corp Anti-cd47 antibodies and uses thereof
CA2999277A1 (en) * 2015-09-21 2017-03-30 Surface Oncology, Inc. Anti-cd47 antibodies and methods of use

Also Published As

Publication number Publication date
ECSP19008417A (es) 2019-02-28
AU2017292752A1 (en) 2019-01-24
KR20190035737A (ko) 2019-04-03
JP2019524087A (ja) 2019-09-05
CL2019000019A1 (es) 2019-06-28
CN109689684A (zh) 2019-04-26
SG11201811788SA (en) 2019-01-30
US11427632B2 (en) 2022-08-30
CN109689684B (zh) 2022-09-23
US20190241654A1 (en) 2019-08-08
AU2017292752B2 (en) 2023-07-27
CA3029977A1 (en) 2018-01-11
IL264009A (en) 2019-01-31
JP7120989B2 (ja) 2022-08-17
MX2019000172A (es) 2019-09-26
CO2019001112A2 (es) 2019-02-19
EP3481862A4 (en) 2020-08-12
WO2018009499A1 (en) 2018-01-11
AR108975A1 (es) 2018-10-17
EA201990218A1 (ru) 2019-07-31
ZA201900070B (en) 2023-08-30
TW201811824A (zh) 2018-04-01
EP3481862A1 (en) 2019-05-15

Similar Documents

Publication Publication Date Title
BR112019000166A2 (pt) anticorpos com baixa imunogenicidade e usos dos mesmos
BR112019008494A2 (pt) anticorpos para pd-1 e usos dos mesmos
ECSP18095014A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
CO2019006485A2 (es) Anticuerpos y metodos de su utilizacion
ECSP19050049A (es) Anticuerpos anti-ox40 y sus usos
BR112018014615A2 (pt) composições de anticorpo para ror1 e métodos relacionados
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
BR112018071307A2 (pt) anticorpos agonistas que ligam cd40 humana e usos dos mesmos
CU20170169A7 (es) Anticuerpos de factor xi
GT201700102A (es) Conjugados de anticuerpo-fármaco
BR112016018408A2 (pt) moléculas de anticorpo à lag-3 e usos das mesmas
BR112019005139A2 (pt) anticorpos anti-il-33 e usos dos mesmos
BR112018010673A2 (pt) moléculas de anticorpo para april e seus usos
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
CR20180605A (es) Anticuerpos anti-cd40 y sus usos
CL2019001434A1 (es) Proteínas de unión a antígeno que se unen al receptor de leptina. (divisional solicitud 201800946)
BR112018012344A2 (pt) anticorpos que se ligam especificamente a hla-dr e seus usos
BR112017012954A2 (pt) composições e métodos para anticorpos que têm como alvo a bmp6
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112018072118A2 (pt) anticorpos de interferona beta e usos dos mesmos
BR112018012884A2 (pt) novos anticorpos anti-mmp16 e métodos de uso
MX2019008779A (es) Antigenos de pseudomonas y combinaciones de antigenos.
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения
CL2021001441A1 (es) Antígenos y anticuerpos de chagas y composiciones, métodos y usos de los mismos (divisional de la solicitud no. 201802932)

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07C Technical examination (opinion): republication [chapter 7.3 patent gazette]

Free format text: REPUBLICACAO DO PARECER 7.1 NOTIFICADO NA RPI NO 2756 DE 31/10/2023.

B09B Patent application refused [chapter 9.2 patent gazette]